RxDoctor Payments Data

Lance Betson, DO

Urogynecology and Reconstructive Pelvic Surgery · Newport Beach, CANPI 1497834964

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (54.0%), food and beverage and gifts — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Intuitive Surgical at 57.8% of the total. Reporting peaked in 2024 at $3,512 and has fallen 86.1% since, to $487 in 2025.

$8,446in general payments, 2019–2025

Across 169 payments — averaging $49.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Medtronic$1K
  • AbbVie$707
  • Boston Scientific$437
  • Pfizer$262
  • Astellas Pharma US Inc$197
  • plus $910 from 18 others

What the payments were for

  • Food & beverage$3,86946%
  • Education$4,56254%
  • Gifts$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,446 in reported general payments places this provider in the 70th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.

See all urogynecology and reconstructive pelvic surgery providers in California

Medicare billing

Part B allowed, 2024
$34,503
Medicare patients
120
Services billed
523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron76$55,503
GemtesaVibegron64$49,462
PremarinEstrogens, Conjugated106$44,108
EstringEstradiol35$18,050
Estradiol132$7,769
Estradiol (Twice Weekly)Estradiol86$6,709
Vivelle-DotEstradiol14$4,691
YuvafemEstradiol15$1,892
Methenamine Hippurate17$1,675
SynthroidLevothyroxine Sodium13$1,191
ClimaraEstradiol13$972
ProgesteroneProgesterone, Micronized37$794
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst35$554
Solifenacin Succinate12$505
NitrofurantoinNitrofurantoin Macrocrystal13$471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin, Estring$262$62,159141 claims
Astellas Pharma US IncMyrbetriq$197$55,50376 claims
Sumitomo Pharma America, Inc.Gemtesa$122$49,46264 claims
AbbVieSynthroid$707$1,19113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.

Other urogynecology and reconstructive pelvic surgery in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →